SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Library > On-Demand Supplier Webinar

BEPO, the enabling technology to long-acting injectable adoption

Format: Webinar | Document type: Supplier Webinar
BEPO, the enabling technology to long-acting injectable adoption

Already in clinical stage, BEPO is MedinCell proprietary long-acting injectable (LAI) platform based on a combination of copolymers, solvent and active pharmaceutical ingredient (API). BEPO provides controlled release of API for days, weeks or months from a fully bioresorbable depot that forms after subcutaneous or local administration. As a game-changing technology, BEPO combines the advantages of alternative drug delivery technologies, including improved patient compliance, efficacy and tolerability but also non-invasive administration, versatility, speed of development and low manufacturing costs.

Speakers:

  • Adolfo Lopez Noriega

    Adolfo Lopez Noriega

    R&D group leader

    MedinCell

  • Louise Lagerqvist

    Louise Lagerqvist

    Business Development Coordinator Coordinator

    MedinCell

  • Stephane Lucchini

    Stephane Lucchini

    Business Director and Strategic Accounts Manager

    MedinCell

Supplier's Info Centre

MEDINCELL